This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Next-Generation Antibody Therapeutics Market 2013-2023

NEW YORK, April 3, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue: Next-Generation Antibody Therapeutics Market 2013-2023

Report Details Therapeutic antibody technologies - find developments and commercial prospectsWhere are therapeutic antibodies heading? Visiongain's updated report gives you revenue predictions to 2023. There you see sales data, R&D trends, outlooks and opportunities. You find the potential of monoclonal antibodies (mAbs) and other immunotechnology. See forecasted sales at overall world market and submarket level. Also assess emerging trends and expected products. Many opportunities remain - you discover the areas to prosper. Forecasts to 2023 and other analyses show you the greatest commercial potentials In our study you find revenue forecasting to 2023, historical data, growth rates and market shares. Also, you see qualitative analysis, business news, prospects and developmental trends (R&D). You receive 54 tables, 34 charts and two research interviews.Our work lets you investigate the most promising and lucrative areas of that biopharma market, helping you stay ahead in knowledge. Reduce the risk of being left behind. Emerging antibody technologies (platforms) hold great promise. The following sections show how you discover their future. Find prospects for the world market and submarketsOur report shows you revenue forecasts to 2023 for these overall world markets: • Therapeutic antibodies (overall sales)• Next-generation therapeutic antibodies.You also find submarket forecasts to 2023 for these next-generation technologies:• Engineered antibodies• Antibody-drug conjugates (ADCs)• Bispecific antibodies (bisAbs)• Antibody fragments and antibody-like proteins• Biosimilar antibody products.Our investigation also discusses what stimulates and restrains business. You find dynamics of the industry and see its potential sales.Demand for those biological drugs (biologics) increases and many products await launch. Find how high revenues can go, discovering segments and years with highest predicted growth.You see what's happening, understanding trends, challenges and opportunities. From 2013 to 2023, that field will contribute much to the pharmaceutical industry. You find the commercial potential.Our work also analyses the main developmental areas. Research and development - assess innovation, trends and possibilitiesFor immunotherapies, what's happening in R&D? You see trends and outlooks there -engineering of antibodies and related agents:• Glycoengineering and Fc amino acid mutations• New antibodies against CD20, HER2 and EGFR targets• Immunoconjugates• Dual ligand systems and other multispecific approaches.Our study also discusses these technologies, among others:• Recombinant antibody mixtures• Bispecific T-cell Engagers (BiTEs)• Designated Ankyrin Repeat Proteins (DARTs)• Domain antibodies, scFvs and other next-generation fragments• Anticalins, Adnectins and other alternative scaffolds.Discover progress. The R&D pipeline for therapeutic antibodies is diverse and promising. You discover innovations affecting the industry's future - hear about developments and find their significance.For large companies and specialty pharma firms there exist many opportunities. Our work explains, covering many issues. What affects therapeutic vaccine technology from 2013? Our report discusses issues and events affecting that industry and market from 2013:• Fusion proteins and other variations on the mAb theme• Targets for new treatments• Oncology - the main focus, especially treating solid tumours• Treatment of other cancers, arthritis, osteoporosis and ophthalmic disorders• Challenges affecting producers of biosimilars.Also, we discuss these aspects of the field:• Fragments vs antibody-like protein• Companion diagnostics and personalised medicine• Improvement of biologics - biobetters• Entry barriers to the antibody technology market.You investigate technological, economic and political questions, exploring leading companies, competition and business outlooks. See what the future holds. Leading companies and 2015 market valueWhat happens next? We predict the world market for therapeutic antibodies will reach $69.6bn in 2015, and expand further to 2023.From 2013, next-generation technologies will gain rising market shares and high revenues. Those drugs hold great scope for investment, technological advances and commercial success. Our study shows you how they progress.You see what products and organisations hold greatest potential. Our work explores these leading companies:RocheKyowa Hakko KirinBristol- Myers SquibbMedImmuneBioWaSeattle GeneticsImmunoGen.Also, we discuss these players and others:AmgenPfizerXencorSanofiBayerBiogen Idec.From 2013 to 2023 there will arise many opportunities. Our work shows you the technological and commercial possibilities. Eight ways Next-Generation Antibody Therapeutics Market 2013-2023 helpsIn particular, then, our investigation gives you the following knowledge:• Revenues to 2023 for the world therapeutic antibodies market - you discover commercial prospects for immunotherapy• Revenues to 2023 for the world next-generation antibodies market and five submarkets - you find sales prospects for emerging technologies• Review of R&D - technology and disease areas - you hear about progress in research and development, assessing technological and clinical possibilities• Discussions of companies - you find activities, products, capabilities and outlooks• Interviews with authorities in the industry - you discover opinions and debates to help you stay ahead• Understanding of competition and opportunities - you see what affects the industry, getting impressions of its future• Discussions of what stimulates and restrains the industry and market - you assess challenges and strengths, helping you compete and gain advantages• Prospects for established firms and those seeking to enter the sector - you explore needs, practices and outlooks for success. You gain information found nowhere elseThat work gives independent analysis. You receive business intelligence found only in our report, seeing where technological and financial prospects are most rewarding.With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, also saving time and getting you recognition for technological and commercial insight.Our knowledge costs only a tiny fraction of potential profits from your understanding that expanding market. See what it holds and what you can gain. Discover prospects to 2023 by ordering now Visiongain's investigation is for everyone needing forward-looking analysis of antibodies and related biologics. You find data, trends and predictions. Please order our report now.Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6

Table of Contents 1. Executive Summary1.1 Next-Generation Antibody Therapeutics: Market Overview1.2 Contents of this Report1.3 Research and Analysis Methods 2. Antibody Therapeutics, Past, Present and Future: Clinical and Commercial Overview, 2013-20232.1 Antibody Therapeutics: Worth More Than $50bn in 20112.1.1 Can Antibody Therapeutic Growth Continue? Forecast for the Market, 2013-20232.1.2 Next-Generation Antibody Technologies: A Revolution in Waiting2.1.3 Next-Generation Antibody Therapeutics Will Capture More than 10% of the Market by 20232.1.4 Which Segments Will Grow Fastest? Next-Generation Market Forecast Breakdown, 2011-20232.2 From First Discoveries to Full Humanisation: The Growth of the Antibody Market2.2.1 Natural Antibodies: Key to the Immune System2.2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)2.2.3 Humanising the MAb2.2.4 Fabs, Fusion Proteins and Other Variations on the MAb Theme2.3 The Next Generation Antibody Therapeutics Market: An Overview2.3.1 Market Shares for Next-Generation Segments, 2011-20232.3.1.1 ADCs Lead the Way, 2011-20122.3.1.2 CAGR Over 100% for Three Segments, 2011-20162.3.1.3 Bispecific Antibodies to Reach 19% Market Shares by, 2017-20232.3.2 Next Generation Antibody Therapeutics: Product Analysis2.3.2.1 Approved Next-Generation Antibody Therapeutics2.3.2.2 More than 80 Products in Clinic2.3.3 Oncology: The Major Focus2.3.4 The Main Targets for Next-Generation Products2.3.5 Regional Markets for Next-Generation Products 3. Engineered Antibodies Market, 2013-20233.1 Engineered Antibodies Market Forecast, 2013-20233.2 Engineered Antibodies: Overview of the Field in 20113.2.1 Antibody Optimisation is the Norm3.2.2 Engineering for a Real Difference: CDC, ADCC and Half-Life3.2.3 Ways to Engineer: Glycosylation and Amino Acid Mutations3.2.4 What are the Platforms? BioWa: Potelligent Removal of Fructose3.2.4.2 Glycart: GlycoMAB for Extra ADCC3.2.4.3 Xencor: XmAb Leads Amino Acid Modification Engineering Pipeline3.2.5 The Pipeline for Engineered Antibodies, 20133.2.5.1 25 Candidates in Clinic, 20133.2.5.2 CD20 and HER Family Major Targets3.2.5.3 Kyowa Hakko Kirin Largest Share of Pipeline by Volume3.2.5.4 The Pipeline in Overview, 20133.3 The Leaders, 20133.3.1 Poteligeo (Kyowa Hakko Kirin): First Glycosylated MAb to Market3.3.1.1 Poteligeo Prospects3.3.1.2 The Revolution will be Personalised: Simultaneous Approval of Companion Diagnostic for Poteligeo3.3.2 GA101: The Leading Glyco-Engineered Antibody3.3.2.1 Can GA101 Take Over From Rituxan? The Battle for the anti-CD20 Market: GA101 as Follow-On3.3.2.3 Is Improved ADCC Enough to Differentiate GA101? Phase 3 Data for GA1013.3.2.5 Subcutaneous Rituxan: An Alternative PLM Approach3.3.3 XmAb 5574 (Xencor): Leading 'Mutant' MAb3.3.3.1 Clinical Trials Progress for XmAb55743.3.3.2 Amino Acid Mutations vs Glycosylation3.3.3.3 XmAb's 'Diverse Toolbox': The Best Engineering Platform?3.4 Other Products in the Pipeline, 20133.4.1 GA201 (Roche): A Solid Tumour Treatment3.4.1.1 EGFR: New Drugs for an Old Target3.4.2 MEDI563 (MedImmune/BioWa): Possible Asthma MAb3.4.2.1 Next-Generation Antibodies Outside the Oncology Area3.4.2.2 Other MedImmune/BioWa Respiratory MAbs3.4.3 MEDI-551 (MedImmune): Option for Cancer and MS3.4.4 KW-2871 (Life Science Pharmaceuticals): Melanoma Treatment3.4.5 Roledumab (LFB): Leading French Plasma Firm Enters Engineered Antibodies Segment3.4.6 AME-133v (Mentrik Biotech): Applied Molecular Evolution Platform3.4.7 Earlier Stage Candidates, 20133.4.8 BIW8962 (Kyowa Hakko Kirin): Myeloma Trial Failure3.4.9 KHK2298 (Kyowa Hakko Kirin): First Product of the KM Mouse Combined Platform 3.4.10 KHK2804 (Kyowa Hakko Kirin): Targeting Tumour Glycans 3.4.11 KHK2866 (Kyowa Hakko Kirin): HB-EGF Binding Candidate 3.4.12 MDX 1411 (Bristol-Myers Squibb): Kidney Cancer Candidate 3.4.13 MDX 1401 (Bristol-Myers Squibb): Non-Fucosylated MDX 060 3.4.14 MDX 1342 (Bristol-Myers Squibb): Third Potelligent Medarex Candidate 3.4.15 RG7116 (Roche): Another Addition to the HER Franchise? 3.4.16 GT-MAB2.5GEX (Glycotope): Lead GlycoBody 3.4.17 GT-MAB5.2GEX (Glycotope): Bio-Better Substitute for Erbitux? 3.4.18 GT-MAB7.3GEX (Glycotope): Another Bio-Better Candidate 3.4.19 LFB-R603 (LFB): Another Entrant in the Anti-CD20 Field 3.4.20 XmAb 2513 (Xencor): Phase 1 Completed 3.4.21 MGAH22 (MacroGenics): Another Independent Platform 3.4.22 MGA271 (MacroGenics): Refractory Cancer Treatment 3.4.23 PF-04605412 (Pfizer): Targeting Integrins 3.4.24 Engineered Antibodies in Preclinical Study, 20133.5 Drivers and Restraints for Engineered Antibodies, 2013 4. Antibody-Drug Conjugates Market 2013-20234.1 Antibody-Drug Conjugates: Market Forecast, 2013-20234.2 ADCs: Overview of the Field in 20134.2.1 Arming Antibodies: Conjugation for Added Potency4.2.1.1 ADCs: Cytotoxic 'Trojan Horses' Gemtuzumab Ozogamicin: A False Start for the Segment4.2.1.3 Radioconjugates: Temporarily in Eclipse?4.2.2 Two Platforms Dominate the Segment4.2.2.1 Seattle Genetics: Out in Front4.2.2.2 ImmunoGen: 10 Clinical-Stage Products4.2.2.3 Other ADC Platforms in Development4.2.3 The ADC Pipeline, 20134.2.3.1 The Biggest Next-Generation Pipeline in 20134.2.3.2 Low Duplication of Targets4.2.3.3 Roche and Bayer Using Both Platforms4.2.3.4 The ADC Pipeline in Overview, 20134.3.Segment Leaders in 20134.3.1 Adcetris (Seattle Genetics): First in Class4.3.1.1 Clinical Data for Adcetris4.3.1.2 'First HL Approval in 30 Years' Expanding Indications for Adcetris: NHL and Other Lymphomas4.3.1.4 Commercial Performance of Adcetris to Date: Possible Cost and Supply Line Issues? Implications for the ADC Field4.3.2 T-DM1 (Roche): First Solid Tumour ADC4.3.2.1 T-DM1's Bumpy Progress Through Trials4.3.2.2 Roche's HER2 Franchise Management4.3.2.3 Patient-Based Pricing4.3.2.4 T-DM1 Vs GA101 as PLM Strategies4.3.3 Inotuzumab Ozogamicin (Pfizer): Another Attempt for Wyeth's Technology4.3.3.1 Clinical Development of Inotuzumab Ozogamicin Pfizer's Biologics Strategy4.4 Other ADCs in Development, 20134.4.1 CDX-011 (Celldex): Completed Phase 24.4.2 RG7593 (Roche): Another Lymphoma Option4.4.3 RG7596 (Roche): A Rituxan Combination Option?4.4.4 SAR3419 (Sanofi): Sanofi Programme in Haematological Cancer4.4.5 Earlier-Stage Candidates, 20134.4.6 IMGN901 (ImmunoGen): Lead Solo Candidate for TAP Platform4.4.7 BT-062 (Biotest): Myeloma ADC4.4.8 Milatuzumab-Dox (Immunomedics): Traditional Chemotherapeutic Redeployed4.4.9 RG7450 (Roche): Targeting STEAP1 4.4.10 RG7458, RG7598, RG7599, RG7600 and RG7636 (Roche): Multiple Roche/Seattle Genetics Collaborations in Process 4.4.11 SAR566658 (Sanofi): A Second Sanofi Programme 4.4.12 Labetuzumab-SN-38 (Immunomedics): Colorectal Cancer Treatment 4.4.13 SGN-75 (Seattle Genetics): Unlicensed SeaGen Candidate 4.4.14 SGN-CD19A (Seattle Genetics): Another In-House Programme 4.4.15 AGS-16C3F (Agensys/Seattle Genetics): Astellas Renews Collaboration 4.4.16 ASG-5ME (Agensys/Seattle Genetics): ADC for Proprietary Antigen 4.4.17 ASG-22M6E (Agensys/Seattle Genetics): Solid Tumour Monotherapy 4.4.18 MLN0264 (Millennium/Seattle Genetics): Treatment for Gastrointestinal Cancers 4.4.19 Undisclosed ADC (Abbott/Seattle Genetics): Squamous Cell Tumour Target? 4.4.20 AMG 595 (Amgen): Amgen Joins the ADC Fray 4.4.21 BAY 79-4620 (Bayer Healthcare): Targeting CA9 4.4.22 BAY 94-9343 (Bayer HealthCare): Bayer Plays the Field 4.4.23 PSMA ADC (Progenics Pharmaceuticals): Prostate Cancer Treatment in Development 4.4.24 IMGN529 (ImmunoGen): CD37 Targeting ADC 4.4.25 IMGN853 (ImmunoGen): Ovarian Cancer Treatment Option? 4.4.26 IMGN338 (ImmunoGen): Another Integrin-Targeting Antibody 4.4.27 BIIB015 (Biogen Idec): CRIPTO in the Crosshairs 4.4.28 MDX-1203 (Bristol-Myers Squibb): Conjugating a Prodrug4.5 Drivers and Restraints for the ADC Market, 2013 5. Bispecific Antibodies Market 2013-20235.1 Bispecific Antibodies: Market Forecast, 2013-20235.2 Bispecific Antibodies: Overview of the Field in 20135.2.1 What Can Bispecifics (bisAbs) Do for the Antibody Field? Recombinant Mixtures: Another Dual-Targeting Method5.2.1.2 Bispecificity: A Concept Whose Time Has Come at Last5.2.1.3 Removab: A Mark of Progress5.2.2 A Fertile Area for R&D5.2.2.1 CD3 FTW: BiTEs and Other Immune-Cell Recruitment Approaches5.2.2.2 Dual Ligand or Receptor Blockers5.2.2.3 Recombinant Antibody Mixtures5.2.3 Assessing the Bispecific Antibodies Pipeline, 20135.2.3.1 12 Products in Clinic, 20135.2.3.2 Cancer Predominates5.2.3.3 Amgen Now the Leader5.2.3.4 Pipeline in Overview5.3 Two Products First to Phase 25.3.1 Blinatumumab (Amgen): The Bispecific Leader5.3.1.1 Performance of Blinatumumab to Date5.3.1.2 A New Option in ALL?5.3.2 Sym004 (Symphogen): Leading Oncology Mixture5.3.2.1 Synergistic Mechanisms of Action5.3.2.2 Merck Deal to Develop Sym0045.4 Other Bispecific Candidates in 20135.4.1 Sym001 (Symphogen): First Recombinant Mixture in Clinic5.4.2 MT110 (Amgen): A Second BiTE at the Clinic5.4.3 MEDI 565 (MedImmune/Amgen): Adneocarcinoma Treatment5.4.4 BAY2010112 (Bayer): Entering the Clinic in Late 20125.4.5 MM-111 ( Merrimack): ErbB2 and ErbB3 Together5.4.6 IMCgp100 (Immunocore): First Fruits of IMMTAC Platform5.4.7 AFM13 (Affimed Therapeutics): Pioneer Tandab5.4.8 TF2 (Immunomedics): Dock-and-Lock Bispecific for Pretargeted Radioimmunotherapy5.4.9 Ertumaxomab and FBT A05 (Fresenius): New Products from First-to-Market German Leaders 5.4.10 Bispecific Platforms at a Preclinical Development Stage, 20135.4.10.1 BiTE Antibodies in Preclinical Work DART Platform (MacroGenics): A New Competitor in the Clinic?5.5 Drivers and Restraints for Bispecific Antibodies, 2013 6. Antibody Fragments and Antibody-Like Proteins Market 2013-20236.1 Antibody Fragments and Antibody-Like Proteins Market Forecast, 2013-20236.2 Antibody Fragments and Antibody-Like Proteins Market Overview, 20136.2.1 Beyond Fab Fragments: The Future of Small Proteins6.2.1.1 Overlap Between Small Proteins and Bispecific Antibodies6.2.1.2 New Technologies for Small Proteins6.2.1.3 Fragments vs Antibody-Like Proteins6.2.2 Many Platforms, No Clear Leader6.2.2.1 Nanobodies: The Largest Platform DARPins: Impacting AMD? Adnectins: Among the Leading Scaffolds6.2.2.4 Other Technology Platforms in this Segment6.2.3 Overview of the Pipeline, 20136.2.3.1 Five Products in Phase 2, 20136.2.3.2 Ophthalmics A Key Target for Small Proteins6.2.3.3 Ablynx Has a Stake in Six of the Clinical Stage Products6.2.3.4 Pipeline in Overview, 20136.3 Two Segment-Leading Products, 20136.3.1 AGN-150998 (Allergan): Long Half-Life, High Binding Specificity6.3.1.1 Improved Delivery Options6.3.1.2 Prospects for AGN-150998: Can It Break Into the Wet AMD Segment? Future DARPins6.3.2 ALX-071(Ablynx): Nebulised Fragment6.3.2.1 A Successor to Synagis?6.4 Other Candidates in Development, 20136.4.1 Ozoralizumab (Ablynx): Life After Pfizer?6.4.2 ALX-0061 (Ablynx): Another RA Option6.4.3 CT-322 (Adnexus): Anti-Angiogenic Scaffold6.4.4 ESBA105 (Alcon): Leading Naked ScFv6.4.4.1 ESBATech's Fragment Technology Now Owned by Novartis6.4.5 ESBA 1008 (Alcon): Another Wet AMD Approach6.4.6 ATN-192 (Ablynx): PEGylated Plan B for RA6.4.7 ALX-0141 (Ablynx): Possible Osteoporosis Treatment?6.4.8 TAS266 (Ablynx): Entering Clinic in 20126.4.9 PRS-050 (Pieris): Another VEGF-Blocking Antibody-Like Protein6.4.9.1 Anticalins: One of the Leading Scaffolds6.4.9.2 Developing Anticalin Candidates6.4.9.3 Future Anticalins 6.4.10 GSK1827771 (GlaxoSmithKline): Domantis Legacy Lives On? 6.4.11 GSK1995057 (GlaxoSmithKline): Respiratory Domain Antibody6.4.11.1 Other GlaxoSmithKline Domain Antibody Programmes 6.4.12 CEP-37247 (Cephalon): Discontinued by Teva 6.4.13 Other Preclinical Platforms in this Segment, 20136.4.13.1 UniBodies (Genmab): Eliminating IgG4 Hinge Regions6.4.13.2 IgNARs (Pfizer): Shark-Derived Antibodies6.4.13.3 Affibodies (Affibody): Smallest Protein Candidates6.4.13.4 Fynomers (Covagen): Versatile Binding Proteins6.4.13.5 Affilins (Scil Proteins): Ubiquitin-Based Molecules6.5 Drivers and Restraints for Antibody Fragments and Antibody-Like Proteins, 2013 7. Biosimilar Antibodies Market, 2013-20237.1 Biosimilar Antibodies Market Forecast, 2013-20237.2. Biosimilar Antibodies: Overview of the Field, 20137.2.1 Biosimilar: Generic or Better? The EU Guidance of 20127.2.1.2 The Field After the EU Guidance7.2.1.3 Challenges Remain in Biosimilar Development7.2.2 Patent Protection: Key to the Market7.2.3 Over 80 Products in Development, Mostly Preclinical7.2.3.1 Multinationals Entering the Sector7.3 Major Targets for Biosimilar Development, 20137.3.1 Biosimilar Substitute for Rituximab: The Biggest Target7.3.1.1 Potential Players in this Space7.3.2 Biosimilar Substitute for Herceptin: Celltrion Leads the Way7.3.3 Biosimilar Substitute for Enbrel: Will Amgen Patent Extension Block the Developers?7.3.4 Biosimilar Substitute for Remicade: Celltrion Out in Front Again7.4 Drivers and Restraints for Biosimilar Antibodies, 2013 8. Qualitative Industry Analysis: Drivers and Restraints, 20138.1 Next Generation Antibody Therapeutics: A Market at the Tipping Point8.2 Many Pathways to More Potency8.3 Differentiation will be the Driver8.4 Biosimilar Antibodies are the Major Catalyst 8.5 Improving Bioanalytics for Next-Generation Products8.6 A PLM Toolkit for Antibody Therapeutics?8.7 From Infusion to Eyedrops: New Delivery Systems 8.8 Smashing Down the Entry Barriers: Will Next-Generation Products Throw Open the Market?8.9 Many Platforms, Many Possibilities8.10 Which Next-Generation Products Can Co-Exist in the Market?8.11 Much is Promised but Little Performed, to Date8.12 Innovation Isn't Everything8.13 Biosimilar Doubts: How Easily Can the Regulatory Pathway be Crossed?8.14 Cost of Goods: If We Build the Antibodies, Will They Come?8.15 The Next-Generation Market's Future Heavily Depends on Breaking Through in Oncology8.16 Next-Generation Products and Personalised Medicine 9. Research Interviews9.1 Interview with Ivan Horak, Symphogen9.1.1 Advantages of Antibody Mixtures9.1.2 Antibody Mixtures for Receptor Degradation9.1.3 Activating the Immune System9.1.4 Symphogen Targets and Programmes9.1.5 Defining Symphogen's Place in the Next-Generation Sector9.1.6 The Next Ten Years9.2 Interview with Professor Arne Skerra, Pieris AG9.2.1 Current 'State of Play' for Alternative Scaffolds9.2.2 Ophthalmic and Systemic Applications for Scaffolds9.2.3 Choosing Targets and Differentiating Products9.2.4 Possible Mechanisms of Action for Antibodies and Scaffolds9.2.5 The Commoditisation of Antibody Technology9.2.6 Scaffolds: The Next Wave 10. Conclusions10.1 Next-Generation Antibody Therapeutics Industry Growing Rapidly 10.2 ADCs will Remain the Dominant Segment 10.3 More Than 80 Products in Development, With Around Ten Leading Technology Platforms 10.4 These New Approaches Can Rejuvenate the Antibody Therapeutics Market List of TablesTable 2.1 Global Antibody Therapeutics Market: Leading Products, Revenues ($bn), Market Shares (%), 2011Table 2.2 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016Table 2.3 Global Antibody Therapeutics Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2023Table 2.4 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016Table 2.5 Next-Generation Antibody Therapeutics Market: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023Table 2.6 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2011-2016Table 2.7 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2017-2023Table 2.8 Regions of an AntibodyTable 2.9 Natural Antibody Mechanisms of ActionTable 2.10 Approved Murine mAbs, 2013Table 2.11 Approved Chimeric MAbs, 2013Table 2.12 Approved Humanised MAbs, 2013Table 2.13 Approved Fully-Human MAbs, 2013Table 2.14 Approved Fab Fragments, 2013Table 2.15 Approved Fusion Proteins, 2013Table 2.16 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), Market Shares (%), 2011-2012Table 2.17 Approved Next-Generation Antibody Therapeutics, 2007-2012Table 2.18 Phase 3 Pipeline for Next-Generation Antibody Therapeutics, 2013Table 2.19 Popular Antigenic Targets for Next-Generation Antibody Therapeutics, 2013Table 3.1 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016Table 3.2 Engineered Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023Table 3.3 Some Common Antibody Enhancements, 2013Table 3.4 Selected Products from the Potelligent Platform, 2013Table 3.5 Selected Products from the Glycart Platform, 2013Table 3.6 Selected Products from the XmAb Platform, 2013Table 3.7 Engineered Antibodies Pipeline, 2013Table 3.8 Comparative Possibilities of Amino Acid Mutation and Glycoengineering for Fc Engineering, 2013 Table 3.9 Selected Engineered Antibodies Pipeline, Phase 2, 2013 Table 3.10 Selected Engineered Antibodies Pipeline, Pre-Phase 2, 2013 Table 3.11 Selected Engineered Antibodies Pipeline, Preclinical, 2013 Table 4.1 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016Table 4.2 ADC Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023Table 4.3 Selected Products from the Seattle Genetics Platform, 2013Table 4.4 Selected Products from the TAP Platform, 2013Table 4.5 Selected Other Platforms Relevant to ADC Segment, 2013Table 4.6 ADCs Pipeline, 2013Table 4.7 Selected ADCs Pipeline, Phase 2, 2013Table 4.8 Selected ADCs Pipeline, Pre-Phase 2, 2013Table 5.1 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016Table 5.2 Bispecific Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023Table 5.3 Selected Products from BiTE Platform, 2013Table 5.4 Selected Other Platforms for Bispecific Molecules, 2013Table 5.5 Selected Recombinant Antibody Mixtures Pipeline, 2013Table 5.6 Bispecific Antibody Clinical Pipeline Overview, 2013Table 5.7 Bispecific Antibody Clinical Pipeline: Phase 2 and Earlier, 2013Table 6.1 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016Table 6.2 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023Table 6.3 Antibody Fragments and Antibody-Like Proteins Segment: Selected Preclinical Platforms, 2013Table 6.4 Antibody Fragments and Antibody-Like Proteins Segment: Clinical Pipeline, 2013Table 6.5 Antibody Fragments and Antibody-Like Proteins Segment: Phase 2 and Earlier Clinical Pipeline, 2013Table 7.1 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2011-2016Table 7.2 Biosimilar Antibodies Segment: Revenues ($m), AGR (%), CAGR (%), Shares of Next-Generation Antibody Therapeutics Market (%), 2017-2023Table 7.3 Leading Antibody Therapeutics: Patent Expiries, 2013-2019Table 7.4 Selected Biosimilar Antibodies Clinical Pipeline, 2013 List of FiguresFigure 2.1 Global Antibody Therapeutics Market: Leading Products, Revenues ($bn), Market Shares (%), 2011Figure 2.2 Global Antibody Therapeutics Market: Revenues ($bn), 2011-2023Figure 2.3 Next-Generation Antibody Therapeutics as Share of Overall Antibody Therapeutics Market: Revenues ($bn), Market Shares (%), 2011Figure 2.4 Next-Generation Antibody Therapeutics Market: Revenues ($m), 2011-2023Figure 2.5 Next-Generation Antibody Therapeutics as Share of Overall Antibody Therapeutics Market: Revenues ($bn), 2011, 2016, 2023Figure 2.6 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), 2011-2023Figure 2.7 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), Market Shares (%), 2011Figure 2.8 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), Market Shares (%), 2012Figure 2.9 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), 2011, 2013, 2015Figure 2.10 Next-Generation Antibody Therapeutics Market, Breakdown by Segment: Revenues ($m), 2017, 2019, 2021, 2023Figure 2.11 Next-Generation Antibody Therapeutics Pipeline by Phase, 2013Figure 2.12 Popular Antigenic Targets for Next-Generation Antibody Therapeutics, 2013Figure 3.1 Engineered Antibodies Segment: Revenues ($m), 2011-2023Figure 3.2 Engineered Antibodies Pipeline by Phase, 2013Figure 3.3 Engineered Antibodies Pipeline by Target, 2013Figure 3.4 Engineered Antibodies Pipeline by Company, 2013Figure 3.5 Drivers and Restraints for Engineered Antibodies, 2013Figure 4.1 ADC Segment: Revenues ($m), 2011-2023Figure 4.2 ADCs Pipeline by Phase, 2013Figure 4.3 ADCs Pipeline by Target, 2013Figure 4.4 ADCs Pipeline by Company, 2013Figure 4.5 Drivers and Restraints for ADCs, 2013Figure 5.1 Bispecific Antibodies Segment: Revenues ($m), 2011-2023Figure 5.2 Bispecific Antibody Clinical Pipeline by Phase, 2013Figure 5.3 Bispecific Antibody Clinical Pipeline by Target, 2013Figure 5.4 Bispecific Antibody Clinical Pipeline by Company, 2013Figure 5.5 Drivers and Restraints for Bispecific Antibodies, 2013Figure 6.1 Antibody Fragments and Antibody-Like Proteins Segment: Revenues ($m), 2011-2023Figure 6.2 Antibody Fragments and Antibody-Like Proteins Segment: Pipeline by Phase, 2013Figure 6.3 Antibody Fragments and Antibody-Like Proteins Segment: Pipeline by Target, 2013Figure 6.4 Antibody Fragments and Antibody-Like Proteins Segment: Pipeline by Company, 2013Figure 6.5 Drivers and Restraints for Antibody Fragments and Antibody-Like Proteins Segment, 2013Figure 7.1 Biosimilar Antibodies Segment: Revenues ($m), 2011-2023Figure 7.2 Biosimilar Antibodies: Drivers and Restraints, 2013

Companies ListedAbbott LaboratoriesAblynx AdnexusAffibodyAffimed Therapeutics AgensysAlconAlexion Pharmaceuticals Alexis Biotech AlgetaAllerganAllozyme AmbrxAmerican Society of Clinical OncologyAmgen AmylinApplied Molecular Evolution AprogenArana TherapeuticsAstellas PharmaAstraZenecaAvesthagenBaxterBayer HealthcareBayer ScheringBayTech Venture CapitalBioconBiogen IdecBiolex TherapeuticsBioTech PharmaBiotecnolBiotest Pharmaceuticals Biovitrum ABBioWa Boehringer IngelheimBorean PharmaBradmer PharmaceuticalsBristol- Myers SquibbCancer Research Technology Cancer Research UK Cell Therapeutics Celldex TherapeuticsCelltechCelltrionCephalonCevec PharmaceuticalsChengdu Hoist Biotech CIMYM BiosciencesCorixa CorporationCovagenCrucellCytomX TherapeuticsDaiichi SankyoDelenex Therapeutics DendreonDiversysDomantisDr. Reddy's Laboratories Dresden University of TechnologyElan PharmaceuticalsEli Lilly Emergent BioSolutionsEpigen BiotechESBATechEuroFarmaEuropean Medicines Agency (EMEA/EMA)FabrusFood and Drug Administration (US FDA)Forbion CapitalFresenius Gedeon RichterGenentechGenmab Gilde Healthcare PartnersGlaxoSmithKline (GSK)Global Life Science VenturesGlycArt Glycotope GTV BiotherapeuticsHanwha Chemical HaptogenHeidelberg PharmaHuman Genome Sciences IBC PharmaceuticalsIgenicaImmunocoreImmunoGenImmunomedicsIsu Abxis Janssen Biotech (formerly Centocor Ortho Biotech)Johnson & Johnson Karolinska Institute Krankenhaus Nordwest ( Frankfurt am Main)Kyowa Hakko KirinLaboratoires Français de Fractionnement et des Biotechnologies (LFB)LG Life Sciences Life Science PharmaceuticalsLonzaLudwig Institute for Cancer ResearchMabgeneMacroGenics MedarexMedImmuneMeiji Seika PharmaMemorial Sloan-Kettering Cancer CenterMentrik BiotechMerck & Co. Merck KGaAMerck SeronoMerrimack PharmaceuticalsMersana TherapeuticsMerus BiopharmaceuticalsMicromet Millennium Pharmaceuticals Ministry of Health, Labour and Welfare (MHLW, Japan)Molecular Partners MorphoSys National Institute for Health and Clinical Excellence (NICE, UK)Nerviano Medical SciencesNovartis Nuclisome OncoscienceOrbiMed Advisors Oslo University HospitalOxford BioMedicaPeptech CorporationPercivia PfizerPharming HealthcarePierisProbiomedProgenics PharmaceuticalsRBC Capital Markets ReceptorLogicRedwood BioscienceRegeneron PharmaceuticalsRoche Roslin InstituteSamsungSandoz SanofiScil ProteinsSeaGen Secure Seattle GeneticsShanghai CP GuojianSoroka University Medical CentreSpectrum PharmaceuticalsSpirogenStadaSutro Biopharma Swedish Orphan Biovitrum Swiss Federal Institute of TechnologySymphogenSyntarga Takeda Pharmaceutical CompanyTechnische Universität MünchenTeva Pharmaceutical IndustriesTG TherapeuticsTufts Centre for Drug Discovery UCB University of Aberdeen University of OxfordViragen ViropharmaWacker BiosolutionsWyeth (now part of Pfizer)XencorZenotech

To order this report: Therapy Industry: Next-Generation Antibody Therapeutics Market 2013-2023

Contact Clare: clare@reportlinker.comUS:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.19 -1.04%
FB $118.06 0.54%
GOOG $695.70 0.48%
TSLA $222.56 -4.20%
YHOO $36.00 -0.03%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,051.12 -12.25 -0.59%
NASDAQ 4,725.6390 -37.5850 -0.79%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs